Survival Boost With Oncolytic Virus Combo in Glioblastoma Subset
The combination of oncolytic DNX-2401 virotherapy with pembrolizumab (Keytruda) failed to meet a phase I/II study's primary endpoint of objective response rate (ORR) in patients with recurrent glioblastoma, but did demonstrate a "notable survival benefit" in select patients. Among 49 patients who received DNX-2401 followed by pembrolizumab, the ORR was…
bubmagMay 16, 2023